[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"visceral-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:visceral-pain":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,125,154,193,218,252],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":106,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":124},"100432171","virtual-reality-for-gi-cancer-pain-to-improve-patient-reported-outcomes-100432171",false,"NCT04907643","Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","Inclusion Criteria:\n\n* Have a primary malignancy of the biliary tract, colon, liver, pancreas, peritoneum, rectum, small intestine, or stomach, with no plan for resection during the study period\n* Tumor types including, but not limited to, adenocarcinoma, squamous cell carcinoma, neuroendocrine tumors, and tumors of mesenchymal origin will be eligible\n* Have clinically significant visceral pain, measured using the standardized NIH PROMIS GI Pain Scale defined as scoring at least 5 points above the nationally normed score\n* Ability to read and write in English\n\nExclusion Criteria:\n\n* Have a condition that interferes with VR usage, including but not limited to seizures, facial injury precluding safe placement of headset, and visual impairments\n* Have cognitive impairment that affects protocol participation. This will be done with a three part cognitive assessment during the initial phone call to assess eligibility followed by consent discussion if eligible.\n* Have brain metastases\n* Have a prognosis of \\\u003C3 months from the time of enrollment per treating oncologist","ALL","18 Years","99 Years",{"count":20,"type":21},360,"ESTIMATED","INTERVENTIONAL",[24],"NA","Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL). Therapeutic virtual reality (VR) has emerged as a promising and evidence-based treatment modality for cancer pain. Users of VR wear a pair of goggles with a close-proximity screen in front of the eyes that creates a sensation of being transported into lifelike, three-dimensional worlds. To date, VR has been limited to short-term clinical trials for cancer pain. Moreover, limited research exists on theory-based VR modalities beyond mere distraction, such as VR that employs acceptance and commitment therapy (ACT) with components of biofeedback and mindfulness. To bridge these gaps, this study seeks to: (1) assess the impact of immersive VR on patient-reported outcomes (PROs), including pain, activity metrics, and opioid use among patients with visceral pain from a digestive tract malignancy; (2) assess differences in PROs, activity metrics, and opioid use between skills-based VR therapy vs. distraction VR therapy; and (3) determine patient-level predictors of VR treatment response in visceral cancer pain.\n\nTo address these aims, the study will measure PROs and opioid use in 360 patients randomized among 3 groups and follow them for 60 days after enrollment: (1) an enhanced VR group receiving skills-based VR; (2) a distraction-based VR group receiving patient-selected VR videos; and (3) a VR sham control group using a VR headset with 2-D content. The results will inform best practices for the implementation of VR for visceral cancer pain management and guide selection of patient-tailored experiences.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105],"Cancer Pain","Visceral Pain","Gastrointestinal Neoplasms","Cancer of Gastrointestinal Tract","Small Intestine Cancer","Pancreas Cancer","Liver Cancer","Colon Cancer","Biliary Tract Cancer","Stomach Cancer","Rectum Cancer","Peritoneal Cancer","Gastrointestinal Cancer Metastatic","Gastrointestinal Cancers - Anus","Gastrointestinal Cancers - Stomach","Gastrointestinal Cancers - Colorectal","Gastrointestinal Cancers - Small Intestine","Small Intestine Cancer Stage III","Small Intestine Cancer Stage IV","Small Intestine Cancer, Recurrent","Pancreas Cancer, Stage III","Pancreas Cancer, Stage IV","Pancreas Cancer, Metastatic","Pancreas Cancer, Recurrent","Liver Cancer Stage IIIa","Liver Cancer Stage IIIb","Liver Cancer Stage IIIc","Liver Cancer Stage IV","Colon Cancer Stage III","Colon Cancer Stage IV","Stomach Cancer Stage III","Stomach Cancer Stage IV","Stomach Cancer Recurrent","Rectum Cancer, Recurrent","Gastrointestinal Cancers - Liver","Anal Cancer","Anal Cancer Stage III","Anal Cancer Stage IV","Anal Cancer Recurrent","Anal Cancer Metastatic","Anal Cancer, Stage IIIA","Anal Cancer, Stage IIIB","Appendix Cancer","Ampullary Cancer","Bile Duct Cancer","Bile Duct Cancer Stage III","Bile Duct Cancer Stage IV","Bile Duct Cancer Stage IVA","Bile Duct Cancer Stage IVB","Bile Duct Cancer Recurrent","Carcinoid Tumor","Carcinoid Tumor of Pancreas","Carcinoid Tumor of Large Intestine","Carcinoid Tumor of GI System","Carcinoid Tumor of Colon","Carcinoid Tumor of Liver","Carcinoid Tumor of Cecum","Carcinoid Tumor of Ileum","Carcinoid Tumor of Rectum","Carcinoid Tumor of the Small Bowel","Carcinoid Tumor of the Stomach","Large Intestine Cancer","Esophagus Cancer","Esophagus Cancer, Stage III","Esophagus Cancer, Stage IV","Esophagus Cancer, Recurrent","Gallbladder Cancer","Gallbladder Cancer Stage III","Gallbladder Cancer Stage IV","Gastric (Stomach) Cancer","Neuroendocrine Tumor","Peritoneum Cancer","Rectal Cancer","Esophagus Cancer, Stage I","Esophagus Cancer, Stage II","Gallbladder Cancer Stage I","Gallbladder Cancer Stage II","Bile Duct Cancer Stage I","Bile Duct Cancer Stage II",[107,108,109,110,111],"Virtual Reality","VR","support","GI cancer","cancer pain","RECRUITING","2026-02-18",{"date":115,"type":116},"2026-02-20","ACTUAL",{"date":118,"type":116},"2021-10-05",{"date":120,"type":21},"2027-03-16",{"name":122,"class":123},"Cedars-Sinai Medical Center","OTHER",1,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":132,"sex":133,"minAge":17,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":143,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":124},"100609054","a-research-study-exploring-how-musculoskeletal-function-and-the-autonomic-nervous-system-relate-to-visceral-pain-in-women-with-and-without-dysmenorrhea-painful-periods-100609054","NCT07209566","A Research Study Exploring How Musculoskeletal Function and the Autonomic Nervous System Relate to Visceral Pain in Women With and Without Dysmenorrhea (Painful Periods).","The Effect of Vaginal Somatovisceral Pain on Hip Extension Mobility and Strength in Women at Mid-cycle With Dysmenorrhea vs. Controls: A Case-control Study","Inclusion Criteria: Non-pregnant women, not taking hormonal birth control, between the ages of 18 and 36 who report regular menstrual cycles are eligible for the study Exclusion Criteria: Participants will be excluded if they are currently pregnant or, have given birth within the preceding six months, are breastfeeding, or are undergoing in-vitro fertilization treatments. Exclusions also include those who have had abdominal, lumbar, or pelvic surgery within the preceding 12 months, suffer from a chronic pain condition, have an active genitourinary infection, are incontinent of bowel or bladder, or have been diagnosed with prolapse of a pelvic organ, severe labral pathology, femoral acetabular impingement (FAI), interstitial cystitis, endometriosis, pelvic inflammatory disease, irritable bowel syndrome, or other pelvic pathology. Participants reporting a cycle length of less than 28 days or longer than 35 days, those with a history of sexual assault, and those who are anovulatory without hormonal BC or amenorrheic will also be excluded.\n\n\\-",true,"FEMALE","35 Years",{"count":136,"type":21},60,[24],"The purpose of this clinical trial is to determine if women with dysmenorrhea demonstrate an increased musculoskeletal and autonomic nervous system response to a painful visceral stimulus compared to controls. A secondary aim is to determine if interoceptive awareness moderates this relationship. The designed methodology aims to elucidate the intricate connections between the interoceptive and musculoskeletal systems in pain perception among female participants, providing valuable insights into the underlying mechanisms of interoceptive pain and functional musculoskeletal changes.",[140,141,28,142],"Dysmenorrhea","Dysmenorrhea Primary","Menstrual Pain",[144],"Effect of visceral organ pain on musculoskeletal and autonomic nervous system","2025-09-29",{"date":147,"type":116},"2025-10-07",{"date":149,"type":116},"2025-08-01",{"date":151,"type":21},"2027-04-01",{"name":153,"class":123},"Azusa Pacific University",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":173,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":189,"leadSponsor":191,"locationsCount":124},"100591303","neurolytic-block-techniques-in-abdominal-visceral-cancer-pain-100591303","NCT06978673","Neurolytic Block Techniques In Abdominal Visceral Cancer Pain","Comparison of Neurolytic Block Techniques for the Treatment of Abdominal Visceral Pain and Their Influence On The Quality of Life of Patients With Cancer","CONCERN","Inclusion Criteria:\n\nPatients aged 18 years or older Presence of localized visceral pain in the upper abdomen originating from cancer of the stomach, duodenum, distal esophagus, ascending or transverse colon, liver, biliary tract, or pancreas\n\nIneffectiveness of analgesic treatment with third-step opioids according to the WHO analgesic ladder, including:\n\nOpioids (≥ 60 mg\u002Fday of morphine equivalents) Antidepressants (tricyclic or dual-action), at any dosage Gabapentinoids, at any dosage Presence of side effects from analgesics that are difficult to manage with medication\n\nExclusion Criteria:\n\nPresence of ascites Presence of deep vein thrombosis Presence of hepatic failure: Child-Pugh class B or C Presence of renal failure: estimated glomerular filtration rate (eGFR) \\\u003C 60 ml\u002Fmin\u002F1.73 m² Use of any anticoagulant medication\n\nClinical coagulation disorder, defined as:\n\nINR \\> 1.5 Prothrombin activity \\\u003C 70% or prothrombin time \\> 13.5 seconds aPTT \\> 40 seconds Cardiovascular failure: NYHA class III",{"count":163,"type":21},64,[24],"The neurolytic blocks of sympathetic chains are commonly used for the treatment of cancer-related pain. This study aims to compare celiac plexus neurolysis and splanchnic nerve neurolysis for the treatment of abdominal visceral pain and its influence on the quality of life of patients with cancer.",[167,168,27,28,169,170,171,172],"Cancer, Malignant Tumors","Abdominal Cancer","Cancer-related Pain","Pain Management","Celiac Ganglia","Sympathetic Ganglia",[111,174,175,176,177,178,179,180,181,182,183],"visceral pain","abdominal cancer","cancer","abdominal pain","cancer-related pain","pain management","neurolytic block","splanchnic nerve block","celiac plexus block","sympathetic neurolysis","NOT_YET_RECRUITING","2025-05-30",{"date":187,"type":116},"2025-06-03",{"date":185,"type":21},{"date":190,"type":21},"2026-12",{"name":192,"class":123},"Instituto do Cancer do Estado de São Paulo",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":200,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":204,"briefSummary":205,"conditions":206,"keywords":207,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":216,"locationsCount":124},"100590876","paragastric-neural-blockade-and-laparoscopic-assisted-transversus-abdominis-plane-block-on-visceral-pain-after-surgery-100590876","NCT06973122","Paragastric Neural Blockade and Laparoscopic Assisted Transversus Abdominis Plane Block on Visceral Pain After Surgery","Effect of Combined Paragastric Autonomic Neural Blockade and Laparoscopic Assisted Transversus Abdominis Plane Block on Visceral Pain After Bariatric Surgery","Inclusion Criteria:\n\n* Age: 20-50 years, both sexes.\n* ASA physical status class I to III.\n* BMI 35- 50 kg\u002Fm²\n\nExclusion Criteria:\n\n* Severe cardiac disorder\n* chronic renal failure\n* liver cirrhosis\n* allergy to bupivacaine\n* patients with history of chronic opioid consumption\n* HBA1C \\> 7%","20 Years","50 Years",{"count":203,"type":21},120,[24],"after laparoscopic bariatric surgery, visceral pain (VP) remains a significant issue. VP causes autonomic symptoms, such as nausea and vomiting, and does not respond to conventional pain management methods that target incisional pain. The present study was performed to test the effect of use of combined paragastric autonomic neural blockade and laparoscopic assisted transversus abdominis plane block on visceral pain during laparoscopic bariatric surgery and in the early postoperative period.",[28],[208,209,174],"paragastric","bariatric surgery","2025-05-13",{"date":212,"type":116},"2025-05-15",{"date":214,"type":116},"2025-04-04",{"date":149,"type":21},{"name":217,"class":123},"Alexandria University",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":229,"conditions":230,"keywords":235,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":251},"100573993","phase-4-intraoperative-autonomic-blockade-for-laparoscopic-cholecystectomy-100573993","NCT06753500","Intraoperative Autonomic Blockade for Laparoscopic Cholecystectomy","Intraoperative Autonomic Blockade to Prevent Early Postoperative Pain After Laparoscopic Cholecystectomy: A Double-Blind, Randomized Controlled Trial","ANB","Inclusion Criteria:\n\n* Elective or emergency laparoscopic cholecystectomy for cholelithiasis with or without cholecystitis.\n\nExclusion Criteria:\n\n* Associated biliary pathologies (e.g., biliary pancreatitis, cholangitis).\n\n  * Additional procedures, such as formal bile duct exploration. Conversion to an open approach\n  * Anesthesia or Surgical complications that require intensive care unit\n* Allergies to local anesthetics",{"count":136,"type":21},[228],"PHASE4","This study proposes infiltrating the hepatoduodenal ligament and the serosal reflection of the gallbladder cystic plate with a combination of Bupivacaine (a long-acting local anesthetic) and Dexamethasone (a corticosteroid). This technique aims to block the hepatic branches of the celiac plexus to improve visceral pain control and its associated clinical manifestations, reduce analgesic requirements, and lower readmission rates, thereby facilitating recovery.",[28,231,232,233,234],"Analgesia","Opioid Use","Postoperative Nausea","Postoperative Vomiting",[236,237,238,239,240,241],"autonomic neural blockade,","Visceral pain","postoperative nausea","Postoperative vomiting","analgesic consumption","opioid use","2025-01-25",{"date":244,"type":116},"2025-01-28",{"date":246,"type":116},"2025-01-15",{"date":248,"type":21},"2025-11-04",{"name":250,"class":123},"Universidad Simón Bolívar",2,{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":132,"sex":133,"minAge":17,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":124},"100555821","effect-of-teas-combined-with-oxycodone-on-postoperative-visceral-pain-in-gynecologic-laparoscopic-patients-100555821","NCT06517069","Effect of TEAS Combined With Oxycodone on Postoperative Visceral Pain in Gynecologic Laparoscopic Patients","Effect of Transcutaneous Electrical Acupoint Stimulation Combined With Oxycodone on Postoperative Visceral Pain and Early Recovery Quality in Gynecologic Laparoscopic Patients","Inclusion Criteria:\n\n* Age 18-65 years\n* American Society of Anesthesiologists grade I-II\n* Body mass index (BMI) 18.5-30 kg\u002Fm2;\n* No ulceration or infection at the acupuncture stimulation site.\n\nExclusion Criteria:\n\n* Allergic to the drugs used in the study;\n* People with unclear consciousness or cognitive dysfunction;\n* There are contraindications of percutaneous acupoint electrical stimulation;\n* Abnormal cardiopulmonary and liver and kidney function;\n* History of analgesic drug use within one week;\n* History of diabetes, myocardial infarction or cerebrovascular accident.","65 Years",{"count":203,"type":21},[24],"To investigate the effect and feasibility of percutaneous acupoint stimulation combined with oxycodone on postoperative visceral pain in laparoscopic patients, and provided a clinical basis for optimizing perioperative pain management in laparoscopic patients.",[28],"2024-07-27",{"date":266,"type":116},"2024-07-30",{"date":268,"type":116},"2024-05-01",{"date":270,"type":21},"2025-07-01",{"name":272,"class":123},"Yangzhou University"]